

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

GP1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gary G. Meadows et al.  
Title: USE OF SEROTONIN AGENTS FOR ADJUNCT THERAPY IN THE TREATMENT OF CANCER  
Docket No.: 618.002US1  
Filed: May 25, 2001  
Examiner: Jerome D. Goldberg  
Serial No.: 09/866,458  
Due Date: December 30, 2001  
Group Art Unit: 1614

Commissioner for Patents  
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Response to Restriction Requirement (2 Pages).

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Katharine A. Jackson Huebsch  
Atty: Katharine A. Jackson Huebsch  
Reg. No. 47,670

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 31 day of December, 2001.

Kandi Latie  
Name

Kandi Latie  
Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

S/N 09/866,458

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gary G. Meadows et al.

Examiner: Jerome D. Goldberg

Serial No.: 09/866,458

Group Art Unit: 1614

Filed: May 25, 2001

Docket: 618.002US1

Title: USE OF SEROTONIN AGENTS FOR ADJUNCT THERAPY IN THE  
TREATMENT OF CANCER

RESPONSE TO RESTRICTION REQUIREMENT

RECEIVED

FEB 04 2002

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Restriction Requirement mailed November 30, 2001, Applicant elects, with traverse, Group I (claims 1-4 and 8-13), directed to a method for the treatment of cancer in a mammal, and to a method for inhibiting the growth of a cancer cell (claims 14-20). In response to the election of species requirement, Applicant further elects the serotonin agent fluoxetine.

The Restriction Requirement is traversed on the basis that restriction requirements are optional in all cases. M.P.E.P. §803. If the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it arguably may include claims to distinct or independent inventions. M.P.E.P. §803. In particular, the claims of Groups I-V are all directed towards uses for serotonin agents. Thus, they can be efficiently and effectively searched and examined with no additional burden placed on the Examiner.

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number if there are any questions regarding this Response or if prosecution of this application may be assisted thereby.

Respectfully submitted,

GARY G. MEADOWS ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 371-2106


Date 31 December 2001


By



Katharine A. Jackson Huebsch  
Reg. No. 47,670

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 31 day of December, 2001.

  
Name

  
Signature